-
In today’s episode we have two short segments, both on bioscience topics:
-
Playing out against the backdrop of a global pandemic (including recent massive surges in regions around the world) is the news that came out a week ago that a candidate “malaria vaccine becomes first to achieve WH...
-
We have two brief segments in today’s episode: News and analysis of the Johnson & Johnson COVID vaccine pause, and the widespread hack of Microsoft Exchange Servers across the country (and the dramatic and unusual ...
-
Today on our news analysis show 16 Minutes — since this show is all about teasing apart what’s hype/ what’s real and where we are on the long arc of innovation — we’re taking a quick pulse-check with the ex...
-
In today’s episode of our news analysis show 16 Minutes, our topic is the ongoing buzz and the mixed news around the Johnson & Johnson vaccine, which was the third vaccine for COVID approved under Emergency Use...
-
A year ago, none of us would believe that mRNA vaccines would be a household name. And yet here we are, at the end of 2020, counting the days towards a vaccine that could not just save lives but help bring us back into a...
-
A vaccine for COVID seems to be (almost) here… or is it? What’s hype/ what’s real beyond the headlines (and beyond the press release), when it comes to the announcement earlier this week from Pfizer and...
-
WHEN are we going to have a COVID-19 vaccine, and how the heck are we going from (what’s been traditionally been up to) 12 years or so of vaccine development compressed into 12 months or so? What will and won’t be co...
vaccines
All vaccines Content
-
In today’s episode we have two short segments, both on bioscience topics:
-
Playing out against the backdrop of a global pandemic (including recent massive surges in regions around the world) is the news that came out a week ago that a candidate “malaria vaccine becomes first to achieve WH...
-
We have two brief segments in today’s episode: News and analysis of the Johnson & Johnson COVID vaccine pause, and the widespread hack of Microsoft Exchange Servers across the country (and the dramatic and unusual ...
-
Today on our news analysis show 16 Minutes — since this show is all about teasing apart what’s hype/ what’s real and where we are on the long arc of innovation — we’re taking a quick pulse-check with the ex...
-
In today’s episode of our news analysis show 16 Minutes, our topic is the ongoing buzz and the mixed news around the Johnson & Johnson vaccine, which was the third vaccine for COVID approved under Emergency Use...
-
A year ago, none of us would believe that mRNA vaccines would be a household name. And yet here we are, at the end of 2020, counting the days towards a vaccine that could not just save lives but help bring us back into a...
-
A vaccine for COVID seems to be (almost) here… or is it? What’s hype/ what’s real beyond the headlines (and beyond the press release), when it comes to the announcement earlier this week from Pfizer and...
-
WHEN are we going to have a COVID-19 vaccine, and how the heck are we going from (what’s been traditionally been up to) 12 years or so of vaccine development compressed into 12 months or so? What will and won’t be co...